A carregar...
DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats
Prolyl hydroxylase (PHD) inhibitors are being developed as alternatives to recombinant human erythropoietin (rHuEPO) for the treatment of anemia in patients with chronic kidney disease (CKD). However, the effects of PHD inhibitors and rHuEPO on blood pressure and CKD in animal models susceptible to...
Na minha lista:
| Publicado no: | J Pharmacol Exp Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The American Society for Pharmacology and Experimental Therapeutics
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6978707/ https://ncbi.nlm.nih.gov/pubmed/31801803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.262782 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|